Abu dhabi: Global and regional pharmaceutical companies have affirmed that the UAE has firmly established itself as a reliable hub within the global pharmaceutical ecosystem, particularly amid rapid shifts in international supply chains and the growing need for more agile and effective responses across the sector. Backed by a wide network of partnerships supported by the Emirates Drug Establishment (EDE), this position demonstrates the strength and attractiveness of the UAE's pharmaceutical business environment, while highlighting the strong institutional confidence and advanced operational integration that define the country's pharmaceutical system.
According to Emirates News Agency, the companies noted that the UAE's international pharmaceutical partnerships go well beyond traditional coordination frameworks, evolving into an effective operational framework built on a clear division of roles between the EDE and its regional and international partners. These efforts have successfully allowed for dynamic adjustments to operational plans in line with shifting demand, helping maintain market stability and ensuring uninterrupted access to treatments for patients.
Saeed bin Mubarak Al Hajeri, Minister of State and Chairman of the Board of Directors of the Emirates Drug Establishment, highlighted the growing presence of leading international partners as a testament to the high level of confidence in the UAE's pharmaceutical sector and the maturity of the regulatory model governing this vital industry. Al Hajeri added that this cooperation forms a fully integrated operational system built on clearly defined roles and collective efforts, strengthening the country's ability to respond to fast-changing developments.
He further clarified that building stronger collaboration with partners is part of a clear strategy to keep the sector sustainable and well-prepared, while ensuring medicines reach the market efficiently and reliably. This reinforces the UAE's growing role as a regional and global hub for pharmaceutical supply chains. He commended the spirit of cooperation and shared commitment demonstrated by industry partners, adding that this institutional collaboration will further strengthen the sector's readiness and operational efficiency.
Ashraf Malak, Managing Director of MSD in the Gulf, Egypt, and Libya, emphasized the company's commitment to supporting the continued availability of medicines and enhancing supply chain efficiency. Malak commended the role of the Emirates Drug Establishment in regulating the sector and strengthening its readiness, reaffirming the importance of integrated efforts among stakeholders to meet patients' needs.
Boyd Chongphaisal, Vice President and General Manager of GSK Gulf, noted the shared responsibility in ensuring the continuity and sustainability of pharmaceutical supplies, particularly during unforeseen circumstances. He praised the Emirates Drug Establishment's proactive regulatory leadership in maintaining supplies of medicine and vaccine stocks at national and regional levels.
Iman Hassenah, General Manager of Amgen Gulf, reiterated the company's commitment to ensuring timely access to treatments for patients. She emphasized that its partnership with the Emirates Drug Establishment will help achieve this goal through continuous coordination that aligns supply plans with patient needs.
Rami Rajab, CEO of Mecomed, highlighted the association's readiness to support the UAE and its healthcare entities in overcoming supply chain challenges. Ahmed Safwat, General Manager of LEO Pharma in the UAE, noted the company's proactive measures to ensure uninterrupted availability of its products, while Mohamed Ezz Eldin of Novartis emphasized the importance of supporting the availability of innovative therapies in the UAE.
Ayman Mokhtar, Regional President for MENA and EURASIA Viatris, explained the company's integrated system from the UAE to manage regional distribution, improving distribution efficiency and maintaining a stable flow of medicines. Roberta Marinelli of Eli Lilly noted the company's efforts in monitoring demand indicators and updating supply levels.
Further contributions came from Preeti Futnani of Sanofi, Mohamed El Shaarawy of Roche, Alaeddin k. Ahmad of Pharma Solution, Sergej Pracevic of Nestl©, and Khaled Abdul Aal of MPC Healthcare, all emphasizing strong collaborative frameworks with the Emirates Drug Establishment. In the manufacturing sector, Madhukar Tanna of Life Pharma stressed the company's commitment to strengthening domestic production capabilities.
Collectively, these statements and commitments, supported by concrete actions, demonstrate a strong collaborative framework between the Emirates Drug Establishment's partners.
